Tag: Cosentyx

April 2, 2019 Off

Novartis’ Cosentyx approved in China for adult psoriasis patients

Novartis got approval from the China Health Authority NMPA for
Cosentyx, its the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

March 5, 2019 Off

Novartis’ Cosentyx does well compared to Janssen’s Stelara, for psoriasis patients

By Dino Mustafić

Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.

January 28, 2019 Off

Novartis’ Cosentyx effective for psoriasis patients, placebo isn’t

By Dino Mustafić

Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, novartis said Monday.

July 6, 2017 Off

Novartis updates label for psoriasis drug in EU

By Dino Mustafić

The Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Novartis’s Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

December 1, 2015 Off

Celyad advances first NKG2D CAR T-Cell Phase I study

By Dino Mustafić

Celyad advances first NKG2D CAR T-Cell Phase I study

November 23, 2015 Off

Green light in EU for Novartis’ Cosentyx

By Dino Mustafić

The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.

November 9, 2015 Off

Cosentyx shows no further progression in joint damage in over 80% of PsA

By Dino Mustafić

Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…

October 26, 2015 Off

Cosentyx in Europe for psoriatic arthritis and ankylosing spondylitis

By Dino Mustafić

Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…

October 12, 2015 Off

Novartis’ Cosentyx provides high level of skin clearance

By Dino Mustafić

Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.

June 15, 2015 Off

Cosentyx meets the primary endpoints

By Dino Mustafić

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms…